Logistic regression analysis of the associations between baseline joint damage and treatment group and increases in erosion and joint space narrowing scores from baseline to week 54
| Model | OR (95% CI) |
| Increase in ERN score from baseline to week 54: | |
| ERN only at baseline | 2.95 (2.55 to 3.41) |
| Treatment with infliximab plus MTX | 0.52 (0.46 to 0.59) |
| Increase in ERN score from baseline to week 54: | |
| JSN only at baseline | 1.80 (1.43 to 2.26) |
| Treatment with infliximab plus MTX | 0.54 (0.47 to 0.60) |
| Increase in ERN score from baseline to week 54: | |
| ERN+JSN at baseline | 3.80 (3.10 to 4.64) |
| Treatment with infliximab plus MTX | 0.54 (0.48 to 0.61) |
| Increase in JSN score from baseline to week 54: | |
| ERN only at baseline | 1.21 (0.88 to 1.66) |
| Treatment with infliximab plus MTX | 0.58 (0.48 to 0.71) |
| Increase in JSN score from baseline to week 54: | |
| JSN only at baseline | 3.99 (3.00 to 5.29) |
| Treatment with infliximab plus MTX | 0.59 (0.48 to 0.72) |
| Increase in JSN score from baseline to week 54: | |
| ERN+JSN at baseline | 6.93 (5.32 to 9.02) |
| Treatment with infliximab plus MTX | 0.60 (0.49 to 0.73) |
ERN, erosion; JSN, joint space narrowing; MTX, methotrexate.